Table 3.
Response rates for patients treated with other DAA options.
| Treatment | n | Treatment duration (weeks) | GT | Cirrhosis (%) | Prior treatment (%) | SVR (%) |
|---|---|---|---|---|---|---|
| Interferon + sofosbuvir + RBV | 2 | 12 (100%) | 3 (100%) | 50% | 0% | 100% |
| Ledipasvir + sofosbuvir ± RBV | 8 | 12 (87%) or 24 (13%) | 1 (62%) and 3 (38%) | 13% | 75% | 100% |
| Sofosbuvir + RBV | 12 | 12 (91%) or 24 (9%) | 2 (100%) | 66%a | 17% | 83% |
| Daclatasvir + simeprevir ± RBV | 18 | 12 (61%) or 24 (39%) | 1 (72%), and 3 (28%) | 88%b | 44% | 94% |
| Interferon + daclatasvir + RBV | 1 | 24 (100%) | 4 (100%) | 0% | 0% | 100% |
a
Three patients missing data.
b
Nine patients missing data. Abbreviations: GT, genotype; RBV, ribavirin; SVR, sustained virological response.